Proleukin (aldesleukin) / Merck (MSD), Prometheus, Novartis, Roche, Iovance Biotherap, Clinigen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

30 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
NCT01909206: A Phase I Trial of Anti-PD-1, Anti-CD137 and TIL

Not yet recruiting
1
24
US
Nivolumab, Anti-PD-1 blocking antibody, BMS-936558, Tumor Infiltrating Lymphocyte (TIL), Cyclophosphamide, Cytoxan, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Fludarabine, Fludara, TIL Infusion, High Dose Interleukin-2 (IL-2), Aldesleukin, Proleukin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Laboratories, National Cancer Institute (NCI)
Metastatic Melanoma
12/16
12/16
NCT03017131: Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
1
9
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Genetically Engineered NY-ESO-1-specific T Lymphocytes, Laboratory Biomarker Analysis
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/20
03/32
NCI-2018-01758, NCT03691376: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
1
4
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, recombinant human interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Cell Therapy, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813
Roswell Park Cancer Institute
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
01/21
01/27
NCT03215810: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed
1
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2, Proleukin®
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Inc., Stand Up To Cancer, Iovance Biotherapeutics, Inc.
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
02/21
06/23
NCT06307301: Study in ALS With Abatacept & IL-2

Active, not recruiting
1
5
US
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis
10/24
10/24
NCT05821153: Low Dose IL2 Immunotherapy in AD

Completed
1
8
US
Aldesleukin
The Methodist Hospital Research Institute
Alzheimer Disease
04/22
04/22
NCT04545827: Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours

Not yet recruiting
1
10
NA
IMM-01, Losartan, Proleukin
Modulate Therapeutics Ltd
Solid Tumor, Solid Carcinoma, Neoplasms, Uveal Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Car. - Esophagus, Renal Cell Carcinoma, Colorectal Cancer, Advanced Cancer
07/22
07/22
NCT03260504: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated
1
6
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1)
University of Washington, Merck Sharp & Dohme LLC, Prometheus Laboratories
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
07/22
07/22
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NCT03068624: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ SLC45A2-specific T Lymphocytes, Autologous SLC45A2-specific CTLs, Autologous SLC45A2-specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
12/22
07/25
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT05483491: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Recruiting
1
42
US
KK-LC-1 TCR-T cells, Aldesleukin 720,000 IU/kg IV every eight hours
Christian Hinrichs, Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey, National Cancer Institute (NCI)
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
09/25
12/28
NYESO SCT, NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated
1
5
US
18F-FHBG, Reporter Probe 18F-FHBG, Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cellular Therapy, Cell Therapy, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Granix, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM)
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
10/23
10/23
NCT06138587: Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Recruiting
1
15
US
Cytokine Induced Memory-like Natural Killer Cells, CIML NK cells, Interleukin-2, Aldesleukin, Proleukin
Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
02/26
11/26
NCT06236425: TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Recruiting
1
15
US
TBio-4101, Tumor-Infiltrating Lymphocyte, Pembrolizumab, Keytruda, Platinum based chemotherapy, Cisplatin, Carboplatin/5-FU, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Aldesleukin, Interleukin-2, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Turnstone Biologics, Corp.
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
05/26
05/26
NCT06152809: CIML NK Cells With Venetoclax for AML

Active, not recruiting
1
10
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin-2, Aldesleukin, Proleukin, IL-2, Venetoclax, C45H50ClN7O7S
Dana-Farber Cancer Institute, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
11/26
11/27
ADP-TILIL7, NCT06204991: To Evaluate the Safety and Efficacy of in Patients With Locally Advanced or Metastatic Melanoma

Not yet recruiting
1
10
NA
ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin
Inge Marie Svane, Adaptimmune
Melanoma Stage III, Melanoma Stage IV, Melanoma
03/26
04/27
NCT01590069: Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, not recruiting
1
70
US
Aerosolized Aldesleukin, Aerosolized Recombinant IL-2, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
04/26
04/26
NCT06395038: IL-2 Plus Abatacept in FTD

Recruiting
1
10
US
Abatacept plus Aldesleukin
The Methodist Hospital Research Institute
Frontotemporal Degeneration
04/26
04/26
NCT06253520: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Recruiting
1
210
US
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
National Cancer Institute (NCI)
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
06/31
06/33
NCT01955460: Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Active, not recruiting
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/24
06/25
NCT05400122: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting
1
12
US
Vactosertib, TEW-7197, EW-7197, EW7197, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, IL-2, Proleukin, Natural Killer Cells
Jennifer Eva Selfridge
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma
12/25
06/26
NCT06190249: Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Suspended
1
12
US
LN-144, Autologous Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Cytoxan, Mesna, Mesnex, Fludarabine, Fludara, Interleukin-2 (IL-2), Aldesleukin, Proleukin, Pembrolizumab, Keytruda
James Isaacs, MD
Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
01/28
07/28
NCT05035407: T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Recruiting
1
100
US
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine
National Cancer Institute (NCI)
Kita-kyushu Lung Cancer Antigen 1, Human
04/25
04/26
NEOG-N100-K01, NCT06107894: TIL Therapy for Patients With Advanced Solid Tumors

Not yet recruiting
1
12
NA
Tumor-infiltrating lymphocytes, NEOG-100, IL-2, Aldesleukin
NeogenTC
Advanced Breast Cancer, Advanced Lung Cancer
09/25
05/26
NCT05989828: A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Not yet recruiting
1
20
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Anti-HLA-A2/NY-ESO1 TCR-transduced Autologous T cells, Autologous Anti-HLA-A2/NY-ESO1 TCR-transduced T Lymphocytes, Autologous HLA-A2/NY-ESO-1-specific TCR Gene-transduced T-lymphocytes, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Echocardiography, EC, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
University of Southern California, National Cancer Institute (NCI)
Triple Negative Breast Cancer
08/26
08/27
NCT01946373: T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Recruiting
1
20
Europe
Cyclophosphamide, Sendoxan, Cytoxan, Neosar, Fludarabine, Fludarabine phosphate, Fludara, T cells, Interleukin-2, IL-2, Proleukin, Dendritic cell vaccine
Karolinska University Hospital
Melanoma
12/25
12/25
NCT05802056: Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Recruiting
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Computerized axial tomography (procedure), Computerized Tomography (CT) scan, Diagnostic Laparoscopy, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), MRIs, sMRI, Structural MRI, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, ABP 206, BCD-263, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Positron emission tomography (procedure)
Mayo Clinic
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
01/26
01/26
NCT05676749: C-TIL051 in Non-Small Cell Lung Cancer

Recruiting
1
20
US
C-TIL051, Pembrolizumab, NKTR-255
AbelZeta, Inc., Nektar Therapeutics
Metastatic Non Small Cell Lung Cancer
03/26
08/27
NEXTGENTIL-ACT, NCT05141474: Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Recruiting
1
10
Europe
NEXTGEN-TIL, Tumor-infiltrating Lymphocyte Adoptive Cell Therapy, Non-myeloablative Lymphodepletion (NMA-LD) Regimen, Cyclophosphamide, Fludarabine, Interleukin-2, IL-2, Aldesleukin
Vall d'Hebron Institute of Oncology, Banc de Sang i Teixits
Epithelial Tumors, Malignant, Malignant Solid Tumor
01/27
01/27

Download Options